Landscape Capital Management L.L.C. Invests $4.16 Million in HealthEquity, Inc. (NASDAQ:HQY)

Landscape Capital Management L.L.C. purchased a new stake in HealthEquity, Inc. (NASDAQ:HQY) in the third quarter, HoldingsChannel.com reports. The fund purchased 50,784 shares of the company’s stock, valued at approximately $4,157,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Mackenzie Financial Corp lifted its holdings in shares of HealthEquity by 16.0% during the 2nd quarter. Mackenzie Financial Corp now owns 2,364,521 shares of the company’s stock worth $203,822,000 after acquiring an additional 325,906 shares during the period. Generate Investment Management Ltd bought a new position in HealthEquity in the second quarter valued at about $24,184,000. Vaughan Nelson Investment Management L.P. raised its stake in HealthEquity by 36.7% during the third quarter. Vaughan Nelson Investment Management L.P. now owns 843,423 shares of the company’s stock worth $69,034,000 after acquiring an additional 226,563 shares in the last quarter. Thrivent Financial for Lutherans lifted its holdings in shares of HealthEquity by 924.2% in the second quarter. Thrivent Financial for Lutherans now owns 220,220 shares of the company’s stock worth $18,983,000 after acquiring an additional 198,718 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of HealthEquity by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 8,768,632 shares of the company’s stock valued at $715,783,000 after purchasing an additional 149,133 shares during the last quarter. Institutional investors own 99.55% of the company’s stock.

Insider Activity

In other HealthEquity news, Director Robert W. Selander sold 8,250 shares of the firm’s stock in a transaction dated Wednesday, October 9th. The shares were sold at an average price of $82.98, for a total value of $684,585.00. Following the completion of the sale, the director now directly owns 54,719 shares in the company, valued at $4,540,582.62. This trade represents a 13.10 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Frank Corvino sold 1,039 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $96.10, for a total value of $99,847.90. Following the transaction, the director now directly owns 3,784 shares of the company’s stock, valued at approximately $363,642.40. This trade represents a 21.54 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 10,536 shares of company stock valued at $884,517. Insiders own 2.20% of the company’s stock.

HealthEquity Stock Performance

Shares of HQY opened at $102.96 on Thursday. HealthEquity, Inc. has a 12-month low of $62.10 and a 12-month high of $103.69. The company has a current ratio of 4.10, a quick ratio of 4.10 and a debt-to-equity ratio of 0.51. The company has a market cap of $8.99 billion, a PE ratio of 85.80, a price-to-earnings-growth ratio of 1.61 and a beta of 0.52. The stock has a 50-day moving average price of $86.66 and a 200-day moving average price of $81.57.

HealthEquity (NASDAQ:HQY) last released its quarterly earnings results on Tuesday, September 3rd. The company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.50 by $0.16. The business had revenue of $299.93 million for the quarter, compared to the consensus estimate of $284.48 million. HealthEquity had a return on equity of 9.01% and a net margin of 9.61%. As a group, equities analysts forecast that HealthEquity, Inc. will post 2.27 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have weighed in on HQY. JMP Securities reaffirmed a “market outperform” rating and set a $105.00 target price on shares of HealthEquity in a research note on Wednesday, September 4th. BTIG Research increased their target price on HealthEquity from $110.00 to $130.00 and gave the company a “buy” rating in a research report on Thursday, November 14th. Bank of America lifted their price target on HealthEquity from $100.00 to $120.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Barrington Research reaffirmed an “outperform” rating and issued a $105.00 price objective on shares of HealthEquity in a research note on Friday, September 20th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $92.00 target price on shares of HealthEquity in a research report on Wednesday, September 4th. One investment analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat, HealthEquity currently has a consensus rating of “Moderate Buy” and a consensus target price of $107.23.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.